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Early life vaccination: Generation of 
adult-quality memory CD8+ T cells 
in infant mice using non-replicating 
adenoviral vectors
Loulieta Nazerai, Maria R. Bassi, Ida E. M. Uddback, Peter J. Holst, Jan P. Christensen & 
Allan R. Thomsen
Intracellular pathogens represent a serious threat during early life. Importantly, even though the 
immune system of newborns may be characterized as developmentally immature, with a propensity to 
develop Th2 immunity, significant CD8+ T-cell responses may still be elicited in the context of optimal 
priming. Replication deficient adenoviral vectors have been demonstrated to induce potent CD8+ T-cell 
response in mice, primates and humans. The aim of the present study was therefore to assess whether 
replication-deficient adenovectors could overcome the risk of overwhelming antigen stimulation during 
the first period of life and provide a pertinent alternative in infant vaccinology. To address this, infant 
mice were vaccinated with three different adenoviral vectors and the CD8+ T-cell response after early 
life vaccination was explored. We assessed the frequency, polyfunctionality and in vivo cytotoxicity 
of the elicited memory CD8+ T cells, as well as the potential of these cells to respond to secondary 
infections and confer protection. We further tested the impact of maternal immunity against our 
replication-deficient adenoviral vector during early life vaccination. Overall, our results indicate that 
memory CD8+ T cells induced by adenoviral vectors in infant mice are of good quality and match those 
elicited in the adult host.
The immune response to viral infection represents the result of a complex interaction between the virus, its target 
cells and several cell subsets belonging to the immune system. There exist a number of differences in the innate 
and adaptive immune system between infants and adults, and these differences are obvious with regard to the 
responses elicited by vaccination and infection1,2.
Viral clearance and disease prevention typically require a combination of humoral and cell mediated immunity. 
It has been suggested that, while antibodies (Abs) are a correlate of protection against (re) infection, T cell immu-
nity is a correlate of protection against primary disease and persistent infection3,4. For effective viral clearance, the 
induction of CD8+ cytotoxic T lymphocytes is often essential and in early life CD8+ T cell responses have been 
suggested to be impaired and delayed5.
T-cell responses elicited in early life have been found to differ from those induced in adult life in terms of 
numbers, diversity of T cell repertoire, and responsiveness to TCR stimulation6. Functionally, there is an impaired 
induction of cytotoxic T cells and an increased Th2 differentiation leading to increased production of IL-5 and an 
increased IgG1/IgG2a ratio, while the capacity to produce IFN-γ is reduced7–9. Until 1996, the neonatal period 
was considered a period in ontogeny during which the immune system was immature and prone to tolerization. 
However, in that year, three studies demonstrated that what was previously believed to represent T-cell tolerance, 
in fact reflected Th2 type immunity. It was further revealed that inoculation of low doses of murine retrovirus led 
to the induction of a protective CTL response, and that absence of a CTL response in high-dose infected mice was 
not the result of immunological immaturity, but correlated with the induction of a non-protective type 2 cytokine 
response10–12. Nevertheless, even today, the mechanism(s) underlying the difference in immune response profile 
of infants and adults are not absolutely clear. However, delayed maturation of certain DC types leading to limited 
IL-12 and type I IFN production combined with the fact that the Th2 cytokine locus is epigenetically poised for 
production of IL-4 and IL-13 may be part of the explanation for the Th2 bias in neonatal immunity13,14.
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The presence of maternal antibodies (Abs) during the first period of life has also been found to represent a 
critical factor that further complicates early life vaccination15,16. Circulating Abs, e.g. in the form of maternal 
Abs, may in theory both augment and inhibit Ab-responses. When Abs are present, non-living antigen may form 
immune complexes and activate complement, and this may differentially impact antigen uptake and presentation 
in various types of APCs16. Immune complexes may directly inhibit B-cell activation through Fcγ RIIB-mediated 
inhibitory signals17. On the other hand, complement split products (C3d) may act as an adjuvant and improve 
immune responses18–20. Regarding CD8+ T cell responses, these typically require live vectors, and circulating 
Abs may reduce CD8+ T-cell mediated immunity by inhibiting vector replication21. For that reason human vac-
cination with current live-replicating attenuated vaccines (i.e. MMR vaccine) is postponed until serum levels of 
maternal Abs have declined to very low values. Nevertheless, it has been demonstrated that even when maternal 
Abs have decreased to non-detectable levels, they might still inhibit vaccination attempts with replicating viruses, 
leaving the infant vulnerable and unprotected against infectious diseases22.
Adenoviral vectors are notorious for their inherent capacity to induce strong and long-lasting CD8+ T cell 
responses against a delivered antigen. The vaccination potential of these vectors may be further improved by link-
ing the encoded antigen to li (MHC class II-associated invariant chain), resulting in an accelerated, augmented 
and prolonged CD8+ T cell response23. Studies so far have established vital knowledge regarding the use of ade-
noviral vectors for vaccination purposes in mice, non-human primates and humans. However, these studies have 
mainly been conducted in immunologically mature, adult hosts. In the present study, we have taken advantage of 
the capacity of adenovectors to elicit CD8+ T-cell responses and employed them to try to induce efficient CD8+ 
T-cell mediated immunity in mice 10–14 days old, hence forth called infant mice. A critical issue in this context 
is finding the optimal vaccination dose. Even in adult mice, high dose immunization and/or systemic vector dis-
semination may lead to generation of partly dysfunctional CD8+ T cells24–27. Given that infant mice are smaller 
and have fewer T cells, one might predict that lower doses should be used to immunize these mice compared to 
adults. Quite surprisingly this was not the case.
As our primary model we chose to work with the lymphocytic choriomeningitis virus (LCMV) infection 
system, exploring the CD8+ T cell response after early life vaccination with Ad-liGP; an adenovector-based vac-
cine encoding the glycoprotein (GP) of LCMV tethered to Ii. It is of interest that the choice of this model allows 
us to directly compare the generation of CD8+ T cells using a non-replicating adenovector to that induced by 
“natural” infection of the same age group with live virus. Thus, for many years it has been known that 17–19 days 
old mice cannot raise a normal CD8+ effector T-cell response and handle LCMV infection appropriately28, and 
more recent studies have documented that in 2-weeks old mice, the LCMV infection follows a protracted course, 
reflecting an impaired CD8+ T-cell response apparently consequential to delayed plasmacytoid dendritic cell 
(PDC) maturation and a deficient type I IFN response5,14. In addition to Ad-liGP, two more adenoconstructs 
encoding CD8+ T-cell epitopes from Yellow Fever virus (YFV): Ad-YF CME and Ad-YF NS3, were investigated 
in the context of early life vaccination. Notably, the efficiency of all vaccine induced responses were tested using 
several different challenge models, all known to reflect CD8+ T-cell mediated protection as validated in one 
or more earlier studies29–35. Overall, our results illustrate that, at least for murine CD8+ T cells, there appear 
to be no major intrinsic functional deficiency, and that given optimal activating conditions efficient CD8+ 
T-cell-mediated immunity may be elicited in infants. On the more translational note, our results suggest that 
replication-deficient adenoviral vectors might represent an efficient and safe tool to induce critical cell-mediated 
antiviral immunity in early life. Importantly, unlike live vectors, maternal immunity to the vaccine was not found 
to negatively impact the induced T-cell response.
Results
Establishing the optimal Ad-liGP vaccination dose in infant mice. Total numbers of T cells in neo-
nates and infants are lower than in adults36, so the first pertinent question was whether mice immunized as infants 
would generate fewer memory CD8+ T cells compared to mice immunized as adults.
However, closely linked to the lower T-cell number in infants, an important question to address was finding 
the vaccine dose required to elicit the most optimal memory CD8+ T-cell response in infant animals. Even in 
adult mice too high a vaccine dose may cause CD8+ T-cell dysfunction24. Thus, to address the importance of 
Ad-liGP dose on the magnitude of the elicited memory CD8+ T cell response after early life vaccination, infant 
mice were vaccinated s.c in the foot pad with different Ad-liGP doses, ranging from 2 × 105 to 2 × 107 pfu, with 
the latter dose representing the optimal dose in adult mice37,38. Mice were subsequently evaluated for the num-
ber and quality of GP specific CD8+ T cells in the spleen 60 d.p.v. Adult mice, vaccinated with 2 × 107 pfu, were 
included for comparison to the optimal IFN-γ response. The results (Fig. 1, for specificity controls see Fig. S1), 
obtained using ICS and flow cytometric analysis, revealed that a dose of 2 × 105 pfu induced a significantly lower 
CD8+ T cell response than seen in optimally immunized adult mice, whereas vaccination of infants with either 
2 × 106 or 2 × 107 pfu resulted in about the same number of splenic memory CD8+ T cells as found in adult 
controls (Fig. 1B).
These findings excluded the use of the 2 × 105 pfu dose for vaccination of infant mice, due to the very low 
numbers of GP specific memory CD8+ T cells elicited, and left the other two doses as potential options. To ensure 
the selection of the dose that would induce the most optimal functional responses in the infants, we next assessed 
the quality of the generated CD8+ T cells elicited by each dose by comparing the mean fluorescence intensity 
(MFI) of IFN-γ + cells (Fig. 1C, for representative plots, see Fig. S2). MFI is a good indicator of the amount of 
IFN-γ released by each antigen-specific CD8+ T cell upon stimulation39. Interestingly, while the MFIs of IFN-γ + 
cells induced by either 2 × 106 or 2 × 107 pfu s.c. did not differ significantly from each other, and both on average 
matched the MFIs of cells from vaccinated adults, mice vaccinated using the lower dose displayed a less uniform 
distribution profile, making us hesitant in selecting this dose as the optimal dose for early life vaccination.
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Next, we asked whether gender might exert any influence in the elicited immune response, and whether the 
spread of the response triggered by the 2 × 106 pfu dose could be gender-related (Fig. S3). However, the statistical 
analysis did not reveal any significant differences, even though female mice vaccinated with 2 × 106 pfu in early 
life displayed a tendency toward a lower response in comparison to male mice of the same group.
Taken together, the above results indicated that a dose of 2 × 107 pfu of Ad-liGP triggers a more consistent 
and reliable immune response in mice vaccinated as infants. However, we reasoned that the characteristics of the 
immune response triggered by 2 × 106 pfu in infants were also worth pursuing, so we continued using both doses 
for some of the following experiments.
Memory CD8+ T cells elicited by early life vaccination with Ad-liGP display good proliferative 
capacity. Having established that the frequency of early life-primed CD8+ T cells can reach adult levels 
60 d.p.v with either of the 2 × 106 pfu or 2 × 107 pfu doses, we next wanted to investigate these CD8+ T cells for 
their ability to rapidly respond to a secondary challenge and proliferate, since efficient clonal expansion is a key 
functionality of good memory cells.
To this end, infant mice were vaccinated s.c in the foot pad with 2 × 106 or 2 × 107 pfu Ad-liGP, and 60 d.p.v 
the mice were challenged i.p with 2 × 106 GP-expressing vaccinia virus (VV-GP)38. Six days post challenge, num-
bers of IFN-γ producing CD8+ T cells in spleen were assessed by ICS and compared to the numbers of IFN-γ 
producing CD8+ T cells present in vaccinated unchallenged mice (Fig. 2). Mice vaccinated as adults, both chal-
lenged and unchallenged, as well as challenged unvaccinated mice, were included for comparison.
We observed that memory CD8+ T cells induced in mice vaccinated as infants and independent of dose 
(2 × 106 or 2 × 107 pfu Ad-liGP), were able to recognise the GP delivered by the vaccinia vector and were able to 
expand as efficiently as memory CD8+ T cells from mice vaccinated as adults.
The findings so far indicate that when infants are vaccinated with an appropriate dose of Ad-liGP, a population 
of long-lived memory CD8+ T cells is generated, which in terms of numbers and proliferative capacity match the 
memory CD8+ T cells produced following Ad-liGP vaccination in adulthood. This seems to be the case for both 
2 × 106 and 2 × 107 pfu Ad-liGP early life vaccination.
Figure 1. Numbers of GP33 specific memory CD8+ T cells in the spleen as a function of vaccine dose used 
for early life vaccination. C57BL/6 infant mice were vaccinated with 2 × 105, 2 × 106 or 2 × 107 pfu Ad-liGP s.c 
in the right hind foot pad and 60 days later IFN-γ producing CD8+ T cells were measured by flow cytometry 
following ex vivo peptide stimulation with GP33-41. (A) Representative dot plots of the IFN-γ producing CD8+ T 
cells for each dose. (B) Absolute numbers of IFN-γ producing CD8+ T cells in the spleen following vaccination. 
(C) Capacity of stimulated cells to produce IFN-γ as indicated by mean fluorescence intensity (MFI) of IFN-γ 
producing cells. Mice, vaccinated as adults with 2 × 107 pfu Ad-liGP, were used as positive controls. Each dot 
represents an individual animal, and the stippled line background. The depicted data are pooled from several 
independent experiments. *p < 0.05.
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Mice vaccinated with Ad-liGP as infants are protected against acute and chronic viral infection. 
Most important for an efficient vaccine is the capacity to induce clinical protection. Therefore, we next tested 
the ability of the Ad-liGP vaccine to induce protection in mice vaccinated as infants by examining the efficiency 
of the generated CD8+ T cells to control a viral challenge. The fact that both 2 × 106 and 2 × 107 pfu could elicit 
memory CD8+ T cells that were able to expand in a recall response, made us employ both doses for this further 
investigation.
For this analysis, infant mice were again vaccinated s.c in the foot pad with either 2 × 106 or 2 × 107 pfu 
Ad-liGP and left for 60 days to reach memory phase. When at memory phase, groups of mice were challenged 
with two different strains of LCMV known to induce either an acute or a more persistent infection. Both these 
challenge models are classical models for evaluation of CD8+ T-cell mediated virus control31,32,34. Furthermore, 
Ad-IiGP vaccination of adult mice has previously been demonstrated to confer CD8+ T-cell mediated 
protection30.
To evaluate vaccine induced protection against an acute infection, the Ad-liGP vaccinated mice, as well as 
a group of naïve mice, were infected i.p with 2 × 105 pfu LCMV Armstrong 53b. Spleens were harvested 3 days 
later for determination of viral titers. As expected, naïve mice did not control the infection and contained high 
levels of virus, whereas mice vaccinated as infants with 2 × 106 or 2 × 107 pfu as well as mice vaccinated as adults 
with 2 × 107 pfu were equally efficient at controlling the infection (Fig. 3A). Interestingly, the splenic viral loads 
matched the CD8+ T cell response profile for each group (Fig. 1B), with the 2 × 106 pfu-early life-vaccinated mice 
displaying slightly higher viral loads than the 2 × 107 pfu early life- and adult life-vaccinated mice. Still, the 2 × 106 
pfu early life-vaccinated mice were clearly protected compared to naïve mice.
To ascertain that the observed protection reflected CD8+ T-cell mediated immunity, the above experiment 
was essentially repeated, but in this case half the vaccinated mice, both mice vaccinated as infants and as adults, 
were depleted of CD8+ T cells prior to challenge. Our results confirmed that CD8+ T cells were the main effector 
in controlling the infection (Fig. S4A), not only in adults as previously demonstrated, but also in mice vaccinated 
as infants.
To address the capacity of the vaccinated mice to handle a higher viral challenge dose and a more chronic 
infection, Ad-liGP vaccinated mice, as well as naïve mice, were infected i.v with 2 × 105 or 2 × 106 pfu LCMV 
Clone 13 and left for 5 or 10 days, respectively32,34. Infection of naïve mice with high doses of LCMV clone 13 
are known to induce profound CD8 T-cell exhaustion and very high viral loads in the organs around day 10 post 
infection, thus explaining the choice of time point for analysis regarding the higher dose of clone 13 challenge34. 
Figure 2. The proliferative capacity of early life induced GP33 specific CD8+ T cells matches that of adult 
primed cells. C57BL/6 infant mice were vaccinated with 2 × 106 or 2 × 107 pfu Ad-liGP s.c in the foot pad and 
60 days later the mice were challenged i.p with 2 × 106 pfu VV-GP. Mice, vaccinated with 2 × 107 pfu Ad-liGP 
as adults (Ctrl) and similarly challenged, were used as positive controls, and unvaccinated, vaccinia challenged 
mice were used to illustrate the unprimed/primary VV-GP induced response. Six days post challenge IFN-γ 
producing CD8+ T cells were enumerated by flow cytometry following ex vivo peptide stimulation with GP33-41. 
CD8+ T-cell numbers with and without VV-GP challenge are depicted; the results regarding unchallenged mice 
are the same as shown in Fig. 1. Each dot represents an individual animal, and the stippled line background. The 
depicted data are pooled from two independent experiments. *p < 0.05.
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Spleens were then collected and the viral loads for each infectious dose were determined. Again, naïve mice were 
unable to control the infection, whereas the spleens of both early life-vaccinated and adult life-vaccinated mice 
were found not to contain detectable levels of virus (Fig. 3B,C). Again, we tested whether clinical protection 
reflected CD8+ T-cell activity by depleting part of the vaccinated mice of CD8+ T cells. Again we observed that 
CD8+ T-cell depletion eliminated all antiviral activity in vivo (Fig. S4B).
Collectively, these data suggest that Ad-liGP vaccination in early life can induce strong anti-viral CD8+ T cell 
immunity that is translated into remarkable levels of in vivo protection against acute and chronic viral infection, 
similar to that seen in mice vaccinated as adults. Notably, even though both 2 × 106 and 2 × 107 pfu doses were 
nearly equally efficient in controlling the challenges applied, we decided at this point to work exclusively with the 
2 × 107 dose for the rest of the evaluations of Ad-liGP early life vaccination-related parameters.
Memory CD8+ T cells generated after early life vaccination are functionally similar to memory 
cells from mice vaccinated as adult. Activated CD8+ T cells employ a number of cellular functions to 
control viral infections like cytolysis of the infected cells via the granule exocytosis pathway, the initiation of pro-
grammed cell death via Fas/FasL interaction and the expression of pro-inflammatory cytokines, such as IFN-γ , 
TNF-α , IL-2 and certain chemokines. Vaccine-induced protection is traditionally correlated with these effector 
functions.
Thus, in order to confirm that the observed in vivo protection in Ad-liGP vaccinated mice mirrors polyfunc-
tionality and the ability of the elicited CD8+ T cells to undergo degranulation, infant mice were vaccinated s.c 
in the foot pad with 2 × 107 pfu Ad-liGP and left for 60 days. Upon reaching the memory phase, splenocytes 
Figure 3. Mice vaccinated in early life can handle both acute and chronic viral infection as efficiently as 
mice primed as adults. C57BL/6 infant mice were vaccinated with 2 × 106 or 2 × 107 pfu Ad-liGP s.c in the 
foot pad and 60 days later challenged i.p with 2 × 105 pfu LCMV Armstrong (A), 2 × 105 pfu LCMV Clone 13 
(B) or 2 × 106 pfu LCMV Clone 13 (C). Mice, vaccinated as adults with 2 × 107 pfu Ad-liGP (ctrl), and naive 
unvaccinated mice were similarly challenged and used as positive and negative controls, respectively. Three 
days (A), 5 (B) or 10 (C) days post challenge, viral titers in the spleen were measured by plaque assay. Each 
dot represents an individual animal. The depicted data are pooled from two independent experiments. The 
detection limit for virus was determined as 250 pfu/g of spleen. *p < 0.05.
www.nature.com/scientificreports/
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were harvested and the CD8+ T cells were examined by ICS for their ability to produce TNF-α , IL-2 and express 
CD107α in addition to IFN-γ production. Degranulation was assessed by incubating the splenocytes with the 
α -CD107α mAb during the 5h peptide stimulation period of the intracellular staining protocol. We observed 
that mice vaccinated as infants or as adults were equally capable of producing CD8+ T cells, which were double 
positive for IFN-γ and TNF-α secretion (TNF-α + IFN-γ +) (Fig. 4A), IFN-γ and IL-2 secretion (IL-2+ IFN-γ +) 
(Fig. 4B), or IFN-γ secretion and degranulation (CD107α + IFN-γ +) (Fig. 4C). Both in mice vaccinated as infants 
and as adults, antigen-specific cells producing IL-2, also frequently produced TNF-α (Fig. S5), indicating that 
vaccine-elicited cells included polyfunctional CD8+ T cells. In this set of experiments we extended the analysis 
to include an additional GP epitope, GP276. This was to ascertain that the observed results were not unique to 
GP33 specific CD8+ T cells. As can be seen from the data, completely similar results were obtained, irrespective 
of the epitope analyzed.
In addition to testing in vitro functionality of the induced memory CD8+ T cells, we also compared the capacity 
of these cells to kill antigen expressing target cells in a standard in vivo cytotoxicity assay. Specifically, spleno-
cytes from CD45.1 mice were pulsed with either relevant peptide (GP33–41) or an irrelevant peptide. Splenocytes 
loaded with GP33-41 were also labeled with CFSE while cells loaded with the irrelevant peptide were left unlabeled. 
CD45.2 mice vaccinated 60 days earlier, along with a group of naïve CD45.2 mice, were injected i.v with equal 
numbers of donor cells loaded with relevant peptides and cells loaded with irrelevant peptide. After 16 hours, 
spleens were collected and flow cytometry was used to quantify the recovery of donor derived cells; specific cyto-
toxicity was calculated according to the formula described in Materials and Methods. We observed that the in vivo 
cytotoxicity, calculated as the shift in the ratio of relevant peptide-loaded cells to irrelevant peptide-loaded cells, 
was similar for both early life- and adult life-vaccinated mice (Fig. S6).
The primary CD8+ T-cell response in Ad-liGP-vaccinated infant mice follows the same kinetics 
as in adult-vaccinated mice. Thus far the data indicate that early life vaccination with Ad-liGP can be as 
efficient as adult life vaccination in inducing efficient CD8+ T-cell memory, and seemingly contradicts the notion 
that a low number of T cells or poor T-cell quality represent an insurmountable restriction to the induction of 
solid CD8+ T cell mediated immunity in early life. However, how the kinetics of CD8+ T-cell expansion follow-
ing early life vaccination compares to that in mice vaccinated as adults is not clear from the above studies.
Consequently, we wanted to monitor the course of the primary CD8+ T cell response after early life vaccina-
tion, and compare it to that following adult vaccination. For this purpose, infant and adult mice were vaccinated 
s.c in the foot pad with 2 × 107 pfu Ad-liGP and the number of antigen specific CD8+ T cells in the spleen was 
determined at several time points between day 9 and day 28 (Fig. 5A+B). We observed that for both groups the 
CD8+ T-cell response peaked on day 12 post vaccination, and even though, for each time point tested, numbers 
of GP specific CD8+ T cells demonstrable in spleen were slightly lower following early life vaccination, we did 
not observe any major delay in CD8+ T-cell expansion in these mice compared to mice vaccinated as adults. 
Accordingly, early life vaccination would be expected to induce clinical protection with about the same delay as 
adult vaccination.
Ad-liGP vaccinated infant mice are able to handle acute and chronic viral infection as early as 
30 days following vaccination. So far, the evaluation of the Ad-liGP -related immune responses has been 
conducted on day 60 post vaccination. Based on the results in the previous section, we wondered how well mice 
vaccinated as infants would be able to control a virus challenge already at 30 days post vaccination.
To address this, infant mice were vaccinated s.c in the foot pad with 2 × 107 pfu Ad-liGP, and 30 days later 
they were exposed to an acute or a chronic infection. As previously, the determination of the viral loads in the 
spleens of vaccinated and naïve mice, following challenge with either 2 × 106 pfu LCMV Clone 13 i.v, or 2 × 105 
pfu LCMV Armstrong 53b i.p was used to gauge the antiviral protection against an acute and a chronic infection, 
respectively (Fig. 6A+B). As expected, naïve mice were incapable of controlling the infection in the spleen. In 
contrast, all vaccinated mice, whether vaccinated during early life or as adults, could consistently control the viral 
infections, they were asked to handle.
Thus, our results indicate that GP specific CD8+ T cells, present as early as 30 days subsequent to vaccination 
of infant mice, are able to control both an acute and a more persistent infection successfully.
Ad-liGP vaccinated mice vaccinated as infants maintain a functionally efficient memory CD8+ 
T-cell population even 180 days following vaccination. The last part of evaluating the use of Ad-liGP 
in early life vaccination was to assess the magnitude of the CD8+ T-cell response and vaccine-induced protection 
at 180 days after vaccination.
Therefore, infant mice were vaccinated s.c in the foot pad with 2 × 107 pfu Ad-liGP and 180 days later numbers 
of IFN-γ secreting CD8+ T cells were assessed by ICS. The results, obtained using flow cytometric analysis, 
revealed that CD8+ T-cell memory was as stable in early life vaccinated mice as in mice vaccinated as adults 
(Fig. 7A).
Having established that good CD8+ T-cell memory could be demonstrated in terms of magnitude for as long 
as 180 d.p.v, we next wanted to gauge this response functionally by testing their ability to protect against viral 
challenge. Thus, infant mice were vaccinated s.c in the foot pad with 2 × 107 pfu Ad-liGP and 180 days later they 
were challenged i.p with 2 × 105 pfu LCMV Armstrong. Mice similarly vaccinated as adults and naïve controls 
were included as controls. Spleens were harvested 3 days later for determination of viral titers (Fig. 6C). In com-
parison to the high viral titers found in the spleens of the naïve mice, all vaccinated mice were able to contain the 
infection.
Overall, our results indicate that there is little decrease in the numbers of GP-specific CD8+ memory 
T cells in the spleens between day 30 and 180 post vaccination (Fig. 7B), suggesting that this CD8+ T-cell 
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memory population is preserved at high levels throughout the time frame studied, for both infant-primed and 
adult-primed CD8+ T cells. Apart from the stable numbers of memory CD8+ T cells, it also appears that these 
cells are functionally qualified to confer antiviral protection.
Figure 4. The functional capacity of CD8+ T cells in Ad-liGP vaccinated infant mice is comparable to 
adults. C57BL/6 infant mice were vaccinated with 2 × 107 pfu Ad-liGP s.c in the foot pad and 60 days later the 
IFN-γ producing CD8+ T cells co-expressing TNF-α (A), IL-2 (B) or CD107α (C) were measured by flow 
cytometry following ex vivo peptide stimulation with GP33-41 or GP276-286. Mice, vaccinated with 2 × 107 pfu Ad-
liGP as adults, were used as controls. Left hand side depict representative plots, while the graphs on the right 
hand side show compiled results from all mice in each group. Each dot represents an individual animal, and bars 
the averages of the test groups. The depicted data are pooled from two independent experiments. *p < 0.05.
www.nature.com/scientificreports/
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Mice are protected from lethal bacterial infection following early life vaccination with 
Ad-liGP. The fact that the Ad-liGP vaccination of adult mice has proved to be highly efficient against viral 
infections has led this principle to be tested also against non-viral pathogens, such as the intracellular bacteria 
Listeria monocytogenes.
Since we have previously shown that Ad-liGP induced CD8+ T cells protect adult mice against recombinant 
L. monocytogenes expressing the GP from LCMV (Lm-GP)29, we wished to take this a step further and investigate 
how early life-vaccinated mice would handle such a challenge.
With that in mind, infant and adult mice were vaccinated s.c in the foot pad with 2 × 107 pfu Ad-liGP and 
60 days later, vaccinated mice, as well as a group of naïve mice, were challenged with a lethal dose of Lm-GP and 
monitored for mortality until day 3 post challenge (Fig. S7).
As expected, the naïve mice were unprotected, with 90% succumbing to infection, while both infant- and 
adult-vaccinated mice had a mortality rate of about 40%. These results suggest that, also in this model, early 
life vaccination with Ad-liGP confers the same levels of protection against a lethal infectious challenge as adult 
vaccination.
Figure 5. Similar kinetics of the primary GP33 specific CD8+ T-cell response in Ad-liGP-vaccinated mice 
regardless of age at vaccination. Groups of C57BL/6 infants and adult mice were vaccinated with 2 × 107 pfu 
Ad-liGP s.c in the foot pad, and on the indicated days following vaccination, spleens were harvested and IFN-Y 
producing CD8+ T cells in spleen were enumerated by flow cytometry following ex vivo peptide stimulation 
with GP33-41. For each time point 5 animals/group of mice vaccinated as infants and 2 animals/group of mice 
vaccinated as adults were analyzed. (A) Representative dot plots for the CD8+ T-cell population and IFN-Y 
producing cells for days 9, 12, 15 post vaccination. (B) absolute numbers of IFN-γ producing CD8+ T cells 
in the spleen. The results represent the group medians with ranges and are representative of two independent 
experiments. *p < 0.05.
www.nature.com/scientificreports/
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The CD8+ T-cell responses triggered by vaccination of infant mice with Ad5-YF vectors are 
comparable to those of mice vaccinated as adults. To expand on the generality of the above results, 
we sought to evaluate the immunogenicity, after early life vaccination, of two different Ad-YF constructs encod-
ing structural or internal proteins of the YF-17D virus. Recent studies employing the Ad-YF CME construct, 
expressing the surface antigens C,M,E, and the Ad-YF NS3 construct, expressing the non-structural protein 3, 
have demonstrated the induction of relevant CD8+ T-cell immunity in adult B6 mice33. The first approach to test 
these vectors for early life vaccination was to evaluate their ability to induce antigen specific memory CD8+ T 
cells and to compare numbers and quality of these cells to those generated by adult immunization. Consequently, 
infant and adult mice were inoculated s.c in the foot pad with 2 × 107 pfu of either of the adeno-constructs and 
were left to reach memory phase. On day 60, numbers of peptide specific IFN-γ producing CD8+ T cells were 
determined as parameter of the expansion of CD8+ T cells in response to the yellow fever epitopes encoded by 
either vector. As can be seen in Fig. 8A, the Ad-YF CME construct induced memory T-cell responses of similar 
magnitude irrespective of age at vaccination. In contrast, the Ad-YF-NS3 vector elicited a slightly lower CD8+ 
T-cell response in infant mice compared to adults.
Infant mice vaccinated with either of the Ad5-YF constructs are significantly protected after 
YF-17D i.c challenge. Having confirmed the immunogenicity of both YF constructs in infant mice, we next 
evaluated vaccine induced protection. In order to do so, infant and adult mice were vaccinated s.c with 2 × 107 pfu 
Figure 6. Ad-liGP vaccinated infant mice are protected against LCMV infection both on day 30 and 180 
post vaccination. C57BL/6 infant mice were vaccinated with 2 × 107 pfu Ad-liGP s.c in the foot pad. (A) 30 days 
after vaccination mice were challenged i.v with 2 × 106 pfu LCMV Clone 13. Ten days post challenge, the viral 
titers were measured by plaque assay. (B,C) 30 or 180 d.p.v mice were challenged i.p with 2 × 105 pfu LCMV 
Armstrong. Three days post challenge, the viral titers were measured by plaque assay. Mice, vaccinated as adults 
with 2 × 107 pfu Ad-liGP, and naive unvaccinated mice were used as positive and negative controls respectively. 
Each dot represents an individual animal. The detection limit for virus was determined as 250 pfu/g of spleen. 
*p < 0.05.
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of the construct in question, and 60 days later all animals, plus naïve controls, were challenged i.c with 104 pfu of 
YF-17D. 7 days later, the viral loads in the brain were investigated.
The determination of viral titers in the brain (Fig. 8B) confirmed previous findings33 showing that the unvac-
cinated challenged mice had high viral loads in the CNS and were unable to clear the infection. No infectious 
virus was recovered from either group of Ad-YF CME -primed mice; this very efficient virus control probably 
reflects the combined effect of both CD8+ T cells and neutralizing antibodies as previously demonstrated in mice 
vaccinated with Ad-CME as adults33. In contrast, and in full agreement with our previous studies, the infection 
was only partly controlled in the Ad-YF NS3-primed mice, and mice vaccinated as infants were not as consistent 
in their capacity to control the infection as were mice primed as adults (Fig. 8B), matching the slightly reduced 
levels of memory CD8+ T cells present in these mice prior to challenge (Fig. 8A).
Maternal immunity to the vector does not interfere with the success of early life vaccination. 
Assuming that early life vaccination with adenevectors became standard, all pregnant mothers would be immune 
to the vector, and we have previously found that vector immunity may significantly reduce the vaccine response37. 
Consequently, we decided to study if maternal immunity might impact on the outcome of early life vaccination 
with replication deficient adenoviral vectors.
For that purpose, 10–14 days old mice were vaccinated s.c. in the foot pad with 2 × 107 pfu Ad-liGP and 60 
d.p.v female mice were selected for breeding. When the offspring of the vaccinated-female mice reached the age 
of 10–14 days, they were themselves vaccinated with 2 × 107 pfu Ad-liGP and 60 d.p.v antigen specific CD8+ T 
cells in the spleens were enumerated by ICS. The responses induced in these mice were compared to those elicited 
in mice, born of un-vaccinated moms and vaccinated as infants. Mice vaccinated as adults were also included for 
comparison. Our results clearly showed that the vaccination status of the mothers did not significantly impact 
the numbers of IFN-γ producing memory CD8+ T cells generated following vaccination with Ad-IiGP (Fig. 9). 
These results imply that maternal immunity to the adenovector-based vaccine construct does not pose an obstacle 
to successful early-life immunization with the same vaccine.
Significant protection even in mice vaccinated 1 day after birth. Finally, we wanted to see if mice 
younger than 10–14 days could be significantly protected by adenovector immunization. To this end, mice born 
1 or 8–9 days earlier were vaccinated with Ad-IiGP. For these experiments, we chose to reduce the vaccine dose 
to 2 × 106 pfu of Ad-IiGP, since we already knew that this dose would work well in the “older” mice, and we did 
not want to overwhelm the immune system in the newborns. Hence, groups of 1 and 8–9 days old mice were 
Figure 7. Memory CD8+ T cells in Ad-liGP vaccinated mice are preserved at high levels on day 180 post 
vaccination regardless of age at vaccination. (A) C57BL/6 infants and adult mice were vaccinated with 2 × 107 
pfu Ad-liGP s.c in the foot pad and 180 days later numbers of IFN-γ producing CD8+ T cells in the spleen were 
determined by flow cytometry following ex vivo peptide stimulation with GP33-41. (B) An overview of memory 
CD8+ T-cell levels as a function of time is also depicted; the results for day 30 and 60 have been taken from 
previous experiments. Each dot represents an individual animal, and the stippled line background. The results 
illustrate the group medians with ranges. *p < 0.05.
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vaccinated either with 2 × 106 pfu of Ad-IiGP or a control vector, and 60 days later all mice were challenged i.c. 
with 20 pfu of LCMV Armstong. Using this route of infection, all naïve mice would die from meningitis, while an 
accelerated CD8+ T-cell response in vaccinated mice would abort the CNS infection and rescue the mice24. As 
it can be seen in Fig. 10, not only did the majority of mice vaccinated at 8–9 days after birth survive the i.c. chal-
lenge - as we expected based on our previous results -, but also mice vaccinated 1 day after birth were significantly 
protected. Thus, vaccination with Ad-IiGP can be used to induce protection even in 1 day old mice.
Discussions
Vaccines have been used to prevent disease for more than 200 years and are responsible for many public health 
successes. However, despite the advances in immunology and molecular biology, viral pathogens like HIV, HBV, 
EBV and HSV remain a threat to the human population. The infant population is even more vulnerable to viral 
infections1,2, and given the distinct immunological features of early life, the design of effective vaccines to be 
administered in infants becomes even more challenging. The widely held view about early life effector T cells is 
that they are intrinsically anti-inflammatory, and that their propensity to differentiate into Th2 cells contributes 
to vaccination failure. Here, we employed a vaccination strategy that is known to induce very potent CD8+ T 
cell responses in adult individuals to try and tackle the problem of early life infectious diseases. Overall, our 
findings indicate that replication-deficient adenoviral vectors might represent a promising platform for early life 
vaccination.
In most of our studies we used the Ad-liGP vector for vaccination of infant mice, and compared the elicited 
GP specific CD8+ T cell response to that of mice similarly vaccinated as adults. Because infant mice contain 
fewer T cells than adults36, and virus dose is a concern even in adult mice vaccinated using adenovectors24,26, we 
started by establishing the vaccine dose required for optimal vaccination of infant mice. Through testing of three 
different doses, we found that the best and most consistent results were elicited using the same dose also found to 
Figure 8. Analysis of immune responses induced by early life vaccination with Ad-YF vectors. C57BL/6 
infant mice were vaccinated with 2 × 107 pfu Ad-YF CME or Ad-YF NS3 s.c in the foot pad. (A) On day 60 
numbers of IFN-γ producing CD8+ T cells in the spleen were determined by flow cytometry following ex 
vivo peptide stimulation with NS3(268-275) and E(4-12). Mice, similarly vaccinated with 2 × 107 pfu Ad-YF CME 
or Ad-YF NS3 as adults, were used as controls. Each dot represents an individual animal, and the stippled line 
background. (B) Vaccinated mice were challenged i.c with 104 pfu YF-17D virus, and 7 days post challenge their 
brains were removed for titrating of virus content (IFA); unvaccinated, but challenged, mice were included for 
comparison. Each dot represents an individual animal. The depicted data are pooled from two independent 
experiments. The detection limit for virus was determined as 100 pfu/g of brains. *p < 0.05.
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be optimal in adult mice, 2 × 107 pfu37. Thus, quite surprisingly, there is no apparent need for a dose adjustment 
related to vaccination age, which is quite practical both when comparing results from mice vaccinated at different 
ages and when designing vaccine programmes for real-life. Moreover, we observed that the induced responses 
were not influenced by gender. Taking into account that a number of studies have shown gender-specific effects 
regarding the impact of vaccination in infancy40–42, this makes the use of adenovectors even more appealing.
Interestingly, we noted that, amongst the doses tested, also 2 × 106 pfu induced a significant immune response. 
However, when we analysed the MFI of the IFN-γ signal in stimulated CD8+ T cells, we observed a substan-
tial interindividual spread, with half of the population displaying an adult quality T-cell response, while the 
other half displayed substantially lower levels of MFI (Fig. 1C). This might reflect the existence of a threshold 
Figure 9. Pre-existing maternal immunity to the vector does not interfere with vaccination efficiency. 
C57BL/6 infant mice were vaccinated with 2 × 107 pfu Ad-liGP s.c in the foot pad and 60 days later female mice 
were selected for subsequent breeding. The offspring of these mothers were vaccinated with 2 × 107 pfu Ad-liGP 
when they reached the age of 10–14 days, and 60 days later GP specific IFN-γ producing CD8+ T cells were 
measured by flow cytometry following ex vivo peptide stimulation with GP33-41. Mice, born from un-vaccinated 
moms and vaccinated with 2 × 107 pfu Ad-liGP as adults, as well as normal mice vaccinated as adults, were used 
as controls. Results are representative of 2 independent experiments. Each dot represents an individual animal.
Figure 10. Vaccination with Ad-liGP as early 1 day after birth confers significant protection against i.c. 
LCMV infection. Newborn (A) and infant (B) C57BL/6 mice were vaccinated s.c. in the foot pad with 2 × 106 
pfu Ad-liGP or a control vector, and 60 days later all mice were challenged i.c with 20 pfu LCMV Armstrong. 
The mortality of the challenged mice were monitored for 14 days. Results are pooled from several experiments.
www.nature.com/scientificreports/
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of responsiveness, which is not crossed in all infants vaccinated using this dose. Since consistency is clearly an 
important issue in vaccination, we preferred to use the 2 × 107 dose for most of our experiments.
When tested for their ability to expand following challenge with VV-GP, infant-primed CD8+ T cells were 
found to have the same proliferative capacity as adult-primed CD8+ T cells. Moreover, apart from good expan-
sion upon a recall challenge, the generated infant-primed memory CD8+ T cells were also functionally apt at 
conferring protection as tested against both an acute and a more persistent infection. Thus, it seems that early life 
vaccination with Ad-liGP induced memory CD8+ T cells that are able to respond and handle a viral invasion as 
efficiently as adult primed cells, both when it comes to speed of virus control and in the context of a more sus-
tained antigenic challenge.
A recent study from Rudd et al., suggested that due to the restricted diversity of the T cell repertoire during 
the first period of life, early life vaccination recruits ‘incomplete’ clonotypes that, even though they transit nor-
mally into the adult memory pool, exhibit restricted recall response during a secondary challenge, and confer 
reduced immunity43. The reason why our results are so different from those previously reported, we do not know, 
but several differences in the set-up should be noticed. First, they used infants that were 7-days old, while we 
worked with infants between 10–14 days old, this might impact the responsiveness and account for some of the 
difference. On the other hand, in Fig. 10 we found that mice as young as 1 day old can be significantly protected 
by adenoviral vaccination. Consequently, the most critical difference is probably that they used live recombinant 
vectors, and this required a dose adjustment between adults and infants, the consequences of which are hard to 
predict. Clearly we do not know the TCR repertoire of the cells recruited by our vaccine regimen neither in adults 
nor in infants, but the question is how important it actually is. Thus, very recently published data indicate that 
the neonatal TCR repertoire rapidly diversifies during chronic antigen stimulation44, as it is believed to be the 
situation with adenovector vaccination45,46. Furthermore, there are data, which indicate that differences in TCR 
composition may be quite effectively compensated by the CD8 co-receptor47. Therefore, most important, from a 
functional point of view we saw little or no difference in the protection afforded by infant and adult primed CD8+ 
T cells. Consequently, based on the results obtained in our study, compared to recently published data on infec-
tion with live LCMV5, we conclude that vaccination with replication deficient adenoviral constructs is superior 
to vaccination with live viruses in early life. The reasons for this are not clear, but it could be speculated that the 
critical role played by type I IFN both in controlling early viral replication and the differentiation of CD8+ T cells 
following infection with live virus may play an important role48,49. Thus, the delayed maturation of PDCs in infant 
mice seems to critically impair responses to live virus14, and even in adult mice absence of IFNAR signalling may 
completely prevent a CD8+ T-cell response to LCMV (ref. 48 and own unpublished data). In contrast, type I 
IFN is reported not to be critical to an adenovector induced CD8+ T-cell response (ref. 50 and own unpublished 
observations have confirmed that this is true also for the response to AdIiGP), and therefore the reduced type I 
IFN signaling in early life would not impact this response. Alternatively, a difference in the ability of infants and 
adults in producing IL-33 could play a role; while induction of a CD8+ T cell response to LCMV is critically 
dependent on IL-33, adenovector immunization is not51.
In complete accordance with their in vivo performance, memory CD8+ T cells, elicited after early life vac-
cination with Ad-liGP, matched adult primed CD8+ T cells in their capacity to produce multiple cytokines 
and degranulate upon antigen recognition ex vivo. We could further show that the in vivo killing capacity of 
infant-primed memory CD8+ T cells is comparable to that of memory cells generated in mice vaccinated as 
adults. Taken together, these findings contradict the widely held notion that early-primed CD8+ T cells are 
functionally impaired and unable to produce multiple cytokines at the same levels as adults52. Indeed, our results 
support the idea that there are no intrinsic defects in the CD8+ T cells early in life, but rather that their activation 
is strictly regulated by the stimulating microenvironment53, and can be successfully triggered under the appropri-
ate circumstances (see also ref. 54).
We additionally checked the antiviral protection conferred 30 and 180 days after vaccination. We observed 
that the CD8+ T cells generated as early as 30 d.p.v as well as the CD8+ T cells persisting 180 days after vacci-
nation were both capable of conferring significant antiviral protection (Fig. 6). Furthermore, we compared the 
magnitude of the elicited CD8+ T cell response at different time-points and found that numbers of virus-specific 
CD8+ T cells in the spleen on day 180 post vaccination remained as high as on day 60, for both infant-primed 
and adult-primed CD8+ T cells (Fig. 7). These findings indicate the long term stability of a protective memory 
population.
In addition to assessing the protection against viral infections, we investigated the protection of early life 
vaccinated mice against the intracellular bacteria Listeria monocytogenes. Jensen et al., have previously demon-
strated that the vaccination potential of Ad-liGP, in adult hosts, is not confined to viral pathogens but can also be 
employed against intracellular bacterial infections29. Here, we found that Ad-liGP vaccination protects both mice 
vaccinated as adults and as infants from a lethal bacterial infection.
Besides Ad-liGP, we evaluated the early life vaccination potential of two additional replication deficient 
Ad5-based vectors encoding YF-17D antigens: one encoding the three viral structural proteins C,M,E (Ad-YF 
CME) and the other the non-structural protein 3 (Ad-YF NS3). The currently used, live attenuated vaccine against 
yellow fever, though successfully applied for many years, has displayed a number of vaccine associated adverse 
effects that have emphasised the need for alternative vaccination strategies. Moreover, the fact that the traditional 
vaccine cannot be administered to certain groups of the population, including infants, has made it relevant to 
explore for other vaccination options. Recently, Bassi et al., showed that both vectors in question confer antiviral 
protection when tested in adult mice, and that CD8+ T cells contribute at a great degree to the overall immu-
nity33. Both constructs were found to elicit potent memory CD8+ T-cell responses in infants as well as in adult 
mice, albeit the response to NS3 was slightly reduced in early life primed mice compared to the response in adult 
mice. Notably, vaccination with the Ad-YF CME vaccine known to induce both neutralizing Abs and CD8+ T 
cell mediated immunity effectively protected all mice against i.c. infection, while the protection conferred by the 
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Ad-YF NS3 construct that relies exclusively on CD8+ T cells33, was not as uniform in mice primed as infants as 
it was in the case of adult primed mice (Fig. 8B). This interindividual variation correlated well with the slightly 
reduced numbers of NS3 specific CD8+ T cells in the former mice. The reason for the slight variation in the 
immunogenicity of different adenoviral vectors in infants versus adults is not known, but clearly it does not 
merely reflect the presence or not of the immune response enhancer Ii. Perhaps variations in the abundance of 
relevant peptides for presentation to the T cells in combination with relevant co-stimulatory signals may play a 
critical role. In this regard it could be of interest to test whether the immunogenicity of NS3 might benefit from 
li-linkage.
A key obstacle to early vaccination is transferred, pre-existing maternal immunity16. For that reason we tested 
whether maternal immunity would interfere with adenovector immunization in early life, and found no evidence 
supporting this possibility; this adds one more attractive feature to adenoviral vectors as delivery platform for 
early life vaccination. In conclusion, our results indicate that there is no major intrinsic functional deficits of 
infant CD8+ T cells, and that vaccination with non-replicating adenovectors leads to optimal conditions for 
T-cell priming even in very young individuals. Thus, adenovector immunization could represent a promising and 
practical solution to the problem of inducing efficient cell mediated immunity in early life.
Materials and Methods
Mice. Adult C57BL/6 (CD45.2) female mice, purchased from Taconic Farms (Ry, Denmark) at the age of 
6–8 weeks old, were used as controls in all experiments. Infant C57BL/6 (CD45.2) mice were bred locally, from 
breeding pairs originating from Taconic Farms; these were introduced into experiments when they reached the 
age of 10–14 days. The breeding cages were checked daily and the precise date of birth was recorded. B6.SJL mice 
(CD45.1) were bred locally from breeding pairs originating from The Jackson Laboratory (Bar Harbor, ME, USA).
All mice were housed under specific pathogen free (SPF) conditions and the mice from outside sources were 
allowed to rest for a week before use.
Ethics statement. Experiments were conducted in accordance with national Danish guidelines 
(Amendment # 1306 of November 23, 2007) regarding animal experiments as approved by the Danish Animal 
Experiments Inspectorate, Ministry of Justice, permission numbers 2009/561-1679 and 2015-15-0201-00623.
Recombinant adenoviral vectors and vaccination. E1-deleted E3 inactivated, human type 5 recom-
binant adenovirus (Ad5) vectors expressing the GP of LCMV tethered to the MHC class II-associated invariant 
chain (Ii) (Ad-liGP), the yellow fever structural proteins core, membrane and envelope (Ad-YF CME), or the yel-
low fever nonstructural protein 3 (Ad-YF NS3) had previously been constructed as described23,33,55. The vaccine 
solutions were prepared by diluting the adenoviral vaccine stocks of Ad-IiGP, Ad-YF CME or Ad-YF NS3 in 
phosphate-buffered saline (PBS) to a final volume of 10 μ l. Prior to vaccination, mice were sedated with isoflurane 
and then injected subcutaneously (s.c) in the right hind footpad with 2 × 105, 2 × 106 or 2 × 107 infectious units 
(IFU) of the adenoviral construct.
Viral challenge. LCMV Armstrong 53b. Mice vaccinated with Ad-liGP were challenged intraperitoneally 
(i.p) with 2 × 105 pfu of LCMV Armstrong 53b (provided by M.B.A Oldstone, Scripps Research, La Jolla, CA), 
diluted in PBS, in a total volume of 300 μ l. Three days post challenge spleens were removed and stored (− 80 °C) 
for plaque analysis. For evaluation of resistance to lethal infection, mice were challenged i.c. with a dose of 20 pfu 
in a volume of 30 μ l.
LCMV Armstrong Clone 13. Mice vaccinated with Ad-liGP mice were challenged intravenously (i.v) with 
2 × 105 or 2 × 106 pfu LCMV Armstrong clone 13 (provided by M.B.A Oldstone, Scripps Research, La Jolla, CA) 
diluted in PBS, in a total volume of 300 μ l. Five or ten days post challenge, respectively, spleens were removed and 
stored (− 80 °C) for plaque analysis.
Vaccinia-GP. Mice vaccinated with Ad-liGP were challenged i.p. with 2 × 106 pfu Vaccinia-GP (origi-
nally obtained from Dr. D.H.L. Bishop (Oxford University, Oxford, U.K.) via Annette Oxenius (ETH, Zürich, 
Switzerland)) diluted in PBS, in a total volume of 300 μ l. Six days post challenge spleens were removed and pre-
pared for intracellular staining.
YF-17D virus. Mice vaccinated with Ad-YF CME or Ad-YF NS3 were challenged intracerebrally (i.c) with 104 pfu 
YF-17D virus (Stamaril, Sanofi Pasteur; reconstituted as recommended by the manufacturer) diluted in PBS, in 
a total volume of 30 μ l. Mice were deeply anaesthetized during this procedure. Seven days post challenge brains 
were removed, snap frozen and stored for Immuno Focus assay (IFA).
Bacterial challenge. Mice vaccinated with Ad-liGP were challenged intravenously (i.v) with a lethal dose of 
Listeria-GP (provided by Drik Schlüter, Institute für Medizinische Mikrobiologie, Otto-von-Guericke Universität 
Magdeburg, Magdeburg, Germany) diluted in PBS, in a total volume of 300 μ l. The preparation of the infectious 
dose included overnight growth of the bacterial stock at 37 °C in BHI (brain heart infusion) to induce growth 
phase, and subsequently a 1 h incubation of 1 ml of this culture in 49 ml of fresh BHI medium. After the 1 hour 
incubation period, OD600 measurement allowed the calculation of the bacterial concentration via a predeter-
mined standard curve. The bacterial dose used for challenge was approx. 0.9 × 106 CFU and was controlled by 
plate culture. Following challenge, mice were monitored for health condition, weight loss and survival until day 
three.
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Splenocyte preparation. Spleens were removed aseptically and transferred to Hanks Balanced Salt 
Solution (HBSS). Single-cell suspensions were obtained by pressing the spleens through a fine steel mesh (70 μ m), 
followed by centrifugation and two washes in HBSS, before re-suspension in RPMI 1640 cell culture medium 
containing 10% FCS supplemented with NaHCO3, 2-ME, L-glutamine, and penicillin-streptomycin.
Flow Cytometry. Approximately 2 × 106 splenocytes were transferred to U-bottom 96 well microtiter plates 
and incubated for 5 hours (37 °C, 5% CO2) with 70 μ l RPMI 1640 cell culture medium (containing 1% L-glutamin, 
1% penicillin, 1% streptomycin, 1% 2-mercaptoethanol (2-ME) and 10% fetal calf serum (FBS)), supplemented 
with 50 μ l IL-2 (50 IU/ml), 50 μ l Monensin (2 μ g/ml) and 30 μ l (1 μ g/ml) of the relevant peptide for stimulation. 
Control samples did not receive any peptide. Following incubation the cells were centrifuged (2000 rpm, 3 minutes), 
washed with FACS buffer with monensin (PBS containing 1% BSA, 0.1% NaN3 and 3 μ M monensin) and incu-
bated for 20 minutes (4 °C, dark) with 50 μ l FACS/Monensin medium containing the relevant surface antibodies 
(1:100). Cells were then washed twice with PBS/monensin medium (3 μ M monensin in PBS) and fixated in 100 μ 
l 2% paraformaldehyde (PFA) & 100 μ l PBS/monensin for 15 minutes (4 °C, dark). Afterwards, cells were washed 
with FACS/monensin medium and incubated for 10 minutes (20 °C, dark) with 200 μ l Saponin medium (PBS 
containing 0,5% Saponin). Next, the cells were incubated for 20 minutes (4 °C, dark) with 50 μ l Saponin medium 
containing the relevant intracellular antibodies (1:100). The cells were subsequently washed twice with Saponin 
medium and finally resuspended in FACS/Monensin medium and stored at 4 °C until flow cytrometry analysis. 
Cell samples were analyzed using FACS LSR II cytometer (BD Biosciences) and the data was analyzed using 
FlowJo software version 7.6.5 (Tree Star).
Antibodies. The following flourochrome-conjugated monoclonal Abs were used for flow cytometry: for 
surface staining: α -CD44–FITC, α -CD8-PerCP–Cy5.5, α -CD44–APC/Cy7, and α -CD107α –ALEXA 488; for 
intracellular cytokine staining (ICS): α -IFN-γ –APC, α -TNF-α –PE/Cy7, and α -IL-2–PE. All antibodies were 
purchased from Biolegend as anti-mouse antibodies.
Peptides. The following peptides were used for stimulation: GP33-41 (LCMV), GP276-286 (LCMV), YF E4-12 
(Yellow Fever), YF NS3268-275 (Yellow Fever)
In vivo cytotoxicity. Single cell suspensions from B6.SJL (CD45.1) splenocytes were prepared as described 
and resuspended in 4 ml HBSS. Cells were then pulsed with 2.5 μ g/ml of either relevant or irrelevant peptide, 
for 30 min (37 °C, 5% CO2). The different cell populations were shaken every 10 min and were washed in PBS 
and subsequently resuspended in warm (37 °C) PBS to a final concentration of 1 × 107 cells/ml. The cell popula-
tions were then mixed with equal volumes of CFSE (Carboxyfluorescein Succinimidyl Ester) or warm PBS and 
subsequently incubated for 10 min (37 °C, 5% CO2) and shaken every 3 min. The labeling was stopped by the 
addition of 1/10 of the volume of FBS. Afterwards, cells were left for 2 min on ice before they were washed twice 
in RPMI containing 10% FBS and once in PBS, followed by filtration through a cell strainer (to avoid clumps). 
The cells were then centrifuged (1200 rpm, 5 min.), resuspended in PBS and mixed in a 1:1 ratio (one cell pop-
ulation loaded with a relevant peptide (GP33) and labeled with CFSE and the other loaded with an irrelevant 
peptide and unlabeled). 300 μ l of the cell mixture were injected i.v into vaccinated B6 (CD45.2) mice or naïve 
controls. 16 hours later the spleens were harvested and single cell suspensions were again prepared by pressing 
the spleens through a 70 μ m mesh. The cells were then centrifuged, resuspended in 4 ml HBSS and then 200 μ 
l of each cell suspension was transferred to a U-bottom 96 well microtiter plate for surface staining. Cells were 
centrifuged (1200 rpm, 5 minutes), resuspended in 50 μ l FACS medium (PBS, 10% rat serum, 1% BSA, and 
0.1% NaN3) containing the relevant surface antibodies (α -CD45.1-APC, diluted 1:100) and left to incubate 
for 20 min (4 °C, dark). Next, the cells were washed twice with Wash medium (PBS and 0.1% NaN3), fixated 
in 200 μ l 1% PFA and stored in 200 μ l FACS medium at 4 °C until flow cytrometry analysis. Cell samples were 
analyzed using Fortessa cytometer (BD Bioscience) and the data was subsequently analyzed using the FlowJo 
7.6.5 software (Tree Star).
The in vivo cytotoxicity was calculated using the following formula56:
Cytotoxicity = 100 - ({(percentage of relevant peptide-pulsed cells in vaccinated mice/percentage of irrelevant 
peptide-pulsed cells in vaccinated mice)*100}/{percentage of relevant peptide-pulsed cells in naive mice/percent-
age of irrelevant peptide-pulsed cells in naive mice}).
Virus titrations. Viral loads in the spleens of mice challenged with LCMV Armstrong 53b or Clone 13 were 
determined by an immune focus assay (IFA) using MC57G cells. Viral loads in the brains of mice challenged 
with YF-17D virus were determined by a Vero (ATCC CCL-81) cell based IFA. In both cases organs were first 
homogenized in PBS to yield 10% organ suspensions, and viral titers were subsequently determined as previously 
described38,57.
In vivo CD8+ T-cell depletion. A combination of two monoclonal antibodies (YTS 169 and YTS 156)58 
was used for in vivo depletion of CD8+ T cells from vaccinated mice prior to and during challenge. Mice to 
be depleted were injected i.p. with 100 μ g of each antibody one day prior to challenge plus 1 and 3 days post 
challenge.
Statistical evaluation. GraphPad Prism Software (version 6) was used for the statistical analysis. 
Quantitative results were compared using a nonparametric Mann-Whitney U-test and a p-value of < 0.05 was 
considered evidence of a statistically significant difference.
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